Clinical Trial News and Research

RSS

Halaven (eribulin mesylate) approved for treatment of liposarcoma

The U.S. Food and Drug Administration today approved Halaven (eribulin mesylate), a type of chemotherapy, for the treatment of liposarcoma (a specific type of soft tissue sarcoma) that cannot be removed by surgery (unresectable) or is advanced (metastatic). This treatment is approved for patients who received prior chemotherapy that contained an anthracycline drug.

28 Jan 2016

Vital Strategies launched to improve global health

A new name in global health - Vital Strategies was launched today, with a mission of reducing disease and premature death and helping to deliver a world where every person has the protection of a strong public health system.

27 Jan 2016

Patients who receive information about coronary artery disease risk make improvements to health behaviors

A new study led by researchers at Brigham and Women's Hospital has found that providing unanticipated information about risk of coronary artery disease during a genetic risk assessment for Alzheimer's disease helped some participants cope with their results, and also motivated participants to make changes to their health behaviors.

27 Jan 2016

Results from STRIVE trial of enzalutamide versus bicalutamide in CRPC published in Journal of Clinical Oncology

Astellas US LLC, a United States (U.S.) subsidiary of Tokyo-based Astellas Pharma Inc., and Medivation, Inc. today announced that results from the STRIVE trial of enzalutamide compared to bicalutamide in men with castration-resistant prostate cancer (CRPC) were published in the Journal of Clinical Oncology.

27 Jan 2016

AVAX announces results of Phase 1/2 OVAX study in patients with advanced ovarian cancer

AVAX Technologies, Inc., a pioneer in personalized cancer vaccines, today announced the results of its Phase 1/2 OVAX study in patients with platinum resistant relapsed Stage III or IV Ovarian Cancer.

26 Jan 2016

Chronic exposure to environmental toxin may up risk of neurodegenerative illness

A new study published today in the science journal Proceedings of the Royal Society B indicates that chronic exposure to an environmental toxin may increase risk of neurodegenerative illness. Conducted by scientists at the Institute for EthnoMedicine, a non-profit medical research organization, and the University of Miami Brain Endowment Bank, the study provides a foundation for future research in Alzheimer's disease, ALS and Parkinson's disease.

25 Jan 2016

Audiologists investigating impact of remote care on cochlear implant users

Audiologists from the University of Southampton are investigating how a new patient-centred approach can help cochlear implant users manage their own care programme.

22 Jan 2016

Biomedical innovation in the UK: an interview with Zahid Latif

The biomedical research base is one of the UK's strengths; over 1500 companies in the Pharmaceuticals and biotechnology area are established in the UK employing over 70,000.

22 Jan 2016

Researchers use ASC secreted factors to create therapeutic factor concentrate for critical limb ischemia

"Critical limb ischemia" (CLI) describes an advanced stage of peripheral artery disease characterized by obstruction of the arteries and a markedly reduced blood flow to the extremities. CLI identifies patients at high-risk for major amputation. The estimated annual incidence of CLI ranges between 500 and 1000 new cases out of one million people per year, with the highest rates among the elderly, smokers, and those with diabetes. CLI is considered to be a critical public health issue. Attempts at revascularization are often unsuccessful.

22 Jan 2016

Simple blood test could predict relapse in AML patients

A simple blood test capable of detecting trace levels of leukaemia cells remaining after intensive chemotherapy has been developed by scientists at the National Institute for Health Research Biomedical Research Centre at Guy’s and St Thomas’ NHS Foundation Trust and King’s College London.

22 Jan 2016

Oxeia accelerating development of neurometabolic treatments for concussions

Oxeia Biopharmaceuticals, Inc., a biotechnology company, is catalyzing the development of first-in-class neurometabolic treatments for concussions and other aspects of brain injury.

21 Jan 2016

AbbVie doses first subject in adalimumab clinical trial using Halozyme's ENHANZE technology

Halozyme Therapeutics, Inc. today announced that AbbVie has dosed the first subject in a clinical trial evaluating the safety and pharmacokinetics of adalimumab with Halozyme's proprietary ENHANZE technology.

21 Jan 2016

Philogen launches Phase III pivotal trial in patients with Stage IIIB/C melanoma

Philogen S.p.A. today announced the launch of a pivotal trial in patients with Stage IIIB/C melanoma, following promising results obtained in a Phase II study with an innovative immunotherapeutic approach.

21 Jan 2016

Immunotherapy could be the future of cancer treatments

For decades most cancers have been treated with the standard of care treatments which typically include surgery, radiation and/or chemotherapy. Now there is talk that immunotherapy represents "the future of cancer treatments."

21 Jan 2016

Mood disorder experts question effectiveness of metyrapone drug

Pioneering research by mood disorder experts at Newcastle University has questioned the effectiveness of metyrapone, a drug suggested to treat depression.

21 Jan 2016

OncoGenex provides update on Phase 2 Spruce trial in patients with untreated metastatic NSCLC

OncoGenex Pharmaceuticals, Inc. announced today that data from the Phase 2 Spruce trial evaluating the combination of apatorsen with carboplatin and pemetrexed in patients with untreated metastatic non-small cell lung cancer (NSCLC) did not reach the statistical significance required to demonstrate a progression-free survival (PFS) benefit.

20 Jan 2016

Diabetes drug fails to show any benefit against pancreatic cancer

A diabetes drug that showed promise in previous studies as an anti-cancer treatment failed to show any benefit in a UNC Lineberger Comprehensive Cancer Center-led study that used pancreatic cancer tissue samples to test sensitivity to the drug.

20 Jan 2016

Physiotherapy and occupational therapy not effective in patients with Parkinson's disease

New research from the University of Birmingham has shown that physiotherapy and occupational therapy do not produce improvements in quality of life for patients with mild to moderate Parkinson's disease.

20 Jan 2016

Study findings may help explain why risk of stroke changes after menopause

Risk of stroke in women may come down to a compound the body produces from estrogen known as 2-methoxyestradiol (2-ME). Furthermore, the compound's therapeutic potential may extend beyond treating stroke in women to healing brain injuries in men, a new study in American Journal of Physiology—Endocrinology and Metabolism reports.

20 Jan 2016

Four USF professors selected as AIMBE College of Fellows

Four University of South Florida professors have been elected to the 2016 College of Fellows of the American Institute for Medical and Biological Engineering (AIMBE): Cesario Borlongan and Shyam Mohapatra from the USF Morsani College of Medicine, USF Health; and Robert Frisina, Jr., and Sudeep Sarkar from the USF College of Engineering.

20 Jan 2016

Clinical Trial News and Research

Halaven (eribulin mesylate) approved for treatment of liposarcoma

Vital Strategies launched to improve global health

Patients who receive information about coronary artery disease risk make improvements to health behaviors

Results from STRIVE trial of enzalutamide versus bicalutamide in CRPC published in Journal of Clinical Oncology

AVAX announces results of Phase 1/2 OVAX study in patients with advanced ovarian cancer

Chronic exposure to environmental toxin may up risk of neurodegenerative illness

Audiologists investigating impact of remote care on cochlear implant users

Biomedical innovation in the UK: an interview with Zahid Latif

Researchers use ASC secreted factors to create therapeutic factor concentrate for critical limb ischemia

Simple blood test could predict relapse in AML patients

Oxeia accelerating development of neurometabolic treatments for concussions

AbbVie doses first subject in adalimumab clinical trial using Halozyme's ENHANZE technology

Philogen launches Phase III pivotal trial in patients with Stage IIIB/C melanoma

Immunotherapy could be the future of cancer treatments

Mood disorder experts question effectiveness of metyrapone drug

OncoGenex provides update on Phase 2 Spruce trial in patients with untreated metastatic NSCLC

Diabetes drug fails to show any benefit against pancreatic cancer

Physiotherapy and occupational therapy not effective in patients with Parkinson's disease

Study findings may help explain why risk of stroke changes after menopause

Four USF professors selected as AIMBE College of Fellows

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer